Media

Corgentech to Host Product Pipeline Update on September 22, 2004

SOUTH SAN FRANCISCO, Calif., Sep 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that it will be hosting an investor briefing to discuss its pipeline beyond current product trials on Wednesday, September 22, 2004 from 9:30 a.m. to 12 p.m. in New York City. The briefing will be webcast and include both audio and presentation slides (details are included below).

"Our goal with this event is to help investors gain a greater understanding of the progress we are making with our diverse research platform beyond edifoligide (E2F Decoy) for the potential treatment of coronary and peripheral artery bypass vein graft failure," said John P. McLaughlin, president and chief executive officer of Corgentech. "We are beginning to address inflammatory diseases and cancer with our TF Decoy technology and we look forward to outlining those exciting additional opportunities more clearly at this session."

In addition to Corgentech senior management, two of the country's leading research and clinical experts in their respective fields will discuss the next generation of targets for which the company is developing TF Decoys: NF-Kappa-B (NF-kB) to treat various inflammatory diseases, and Hypoxia-Inducible Factor (HIF) to treat a wide range of cancer types.

    Speakers and Agenda:

Thomas S. Kupper, MD, T.B. Fitzpatrick Professor of Dermatology at Harvard Medical School, will speak about NF-kB and its role in inflammation. NF-kB is a central regulator of immune and inflammatory responses and blocking it reverses the progression of several chronic inflammatory diseases. Dr. Kupper also serves as the Chairman of the Department of Dermatology at Brigham and Women's Hospital and as a Director of the Cutaneous Oncology Program, Dana Farber Cancer Institute as well as Co-Director of the Melanoma and Cutaneous Oncology Program, Dana Farber Harvard Cancer Center.

Gregg L. Semenza, MD, PhD, Professor, Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, and Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, will describe the implications of targeting HIF, a transcription factor that drives tumor angiogenesis, invasion and survival. It is over-expressed in many common cancers and over-expression is associated with increased mortality. Dr. Semenza is a world authority on oxygen homeostasis and was the first scientist to clone HIF-1 and to develop the HIF-1 knock-out mouse. He has multiple collaborations investigating the role of HIF-1 in tumor progression. He also serves as Director of the Program in Vascular Cell Engineering at the Institute for Cell Engineering, Johns Hopkins University.

Leslie M. McEvoy, Ph.D., Corgentech Vice President of Research, will describe the company's programs to develop highly specific, selective and potent TF Decoys to NF-kB and HIF. She will detail the company's development plan for these exciting product candidates.

James Z. Huang, Corgentech Vice President of Business Development and Commercial Operations, will provide a market overview for therapies addressing diseases where NF-kB or HIF are implicated.

Transcription Factors and TF Decoys

Transcription factors (TF) are proteins that regulate genes thereby controlling the biological processes of human cells. Our TF Decoys represent a novel and proprietary method for regulating genes by blocking certain transcription factors. Since abnormal gene expression is a fundamental cause of many diseases, targeting transcription factors offers an attractive therapeutic approach to treat many unmet medical needs. Our lead product is a TF Decoy, edifoligide, (E2F Decoy) which is in Phase 3 clinical trials for the prevention of bypass vein graft failure.

Webcast Details

To access the live webcast or the subsequent archived recording, log on to www.corgentech.com and follow the links from the company's home page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF Decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF Decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation all statements related to our clinical trials and progress with developing product candidates. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of TF Decoys, progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support its operations and other risks detailed in relevant filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Richard Powers of Corgentech, +1-650-624-9600, or
[email protected]; or Daryl Messinger of WeissComm Partners,
+1-415-999-2361, or [email protected], for Corgentech

http://www.corgentech.com

News Provided by COMTEX